Business
Inspire Medical Systems, Inc. Publishes Inspire V Data at ISSS/AAO-HNS Meetings
MINNEAPOLIS, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today published Inspire V clinical outcomes data from its Singapore clinical study as well as the Company’s limited market release in the United States including single site experience at two leading centers. These data will be
About this update from Inspire Medical Systems, Inc.
[{"type":"image","alt":"Inspire Medical Systems","displaySize":"","headline":null,"caption":"Inspire Medical Systems","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":95,"url":"https://media.zenfs.com/en/globenewswire.com/98bfab199b9d39d428b51783fc805b5d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/J27WasQA1o1J0GPVgccp_w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/98bfab199b9d39d428b51783fc805b5d","width":300,"height":95}},"lazy":false},{"type":"text","content":"MINNEAPOLIS, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today published Inspire V clinical outcomes data from its Singapore clinical study as well as the Company’s limited market release in the United States including single site experience at two leading centers. These data will be presented at the American Otolaryngology-Head and Neck Surgery (AAO-HNS) and International Surgical Sleep Society (ISSS) meetings being conducted in Indianapolis between October 9 and October 14.","length":695,"tagName":"p"},{"type":"text","content":"“We are incredibly excited to publish first-time clinical evidence on the Inspire V system. The design of the Inspire V system captures experience built over 25 years with Inspire therapy including over 100,000 patients implanted, and we are proud to provide the initial data from this advanced platform,” stated Tim Herbert, Chairman and Chief Executive Officer of Inspire Medical Systems. “Our initial experience raises the bar for what a successful therapy needs to achieve for both safety and efficacy. The data show that the Inspire V system provides very high and consistent patient adherence of over six hours per night which a patient’s physician can monitor with our SleepSync™ patient management platform.”","length":716,"tagName":"p"},{"type":"text","content":"“The data presented at the ISSS/AAO-HNS meetings in Indianapolis this weekend demonstrate the benefits that Inspire therapy brings to the many patients struggling with OSA,” stated Paul Hoff, M.D., M.S., Inspire Vice President, Senior Medical Director. “The strong safety, superior respiratory sensing, and incr...